Acorda Therapeutics News

New Research Presented at 4th Collaborative Meeting of CMSC and ACTRIMS Expands Understanding of MS-Related Walking Impairment and Clinical Usage of AMPYRAA HAWTHORNE, N.Y. -- -- Acorda Therapeutics, Inc.

Acorda Therapeutics, Inc. , makers of Ampyra , today announced the launch of Ampyra Dialogues, the first-ever online talk show where patients and medical experts talk about how walking problems affect people living with MS.

Acorda Therapeutics opened at 22.91 on Friday. Acorda Therapeutics has a 1-year low of $18.36 and a 1-year high of $33.48. The company has a market cap of $918.6 million and a price-to-earnings ratio of 23.84. Acorda Therapeutics last released its earnings data on Thursday, May 3rd.

Three strikes and you're out? In 2006, the FDA noticed that Acorda Therapeutics was having difficulty submitting serious and unexpected adverse even reports within 15 days of receiving such information as required by law.

Prior to virtualization, we were spending a lot of time managing our infrastructure, with all those physical servers.